If CCR5 blockade is completely protective against covid, as it is against the most common HIV strain, then there will be zero double CCR5delta32 mutants in any covid trial.

Because just as with HIV, double CCR5 mutants are immune.

So if the theory is true, there are no double mutant CCR5 people in any covid trial anywhere on the planet.

But most CCR5 mutants are only single mutants (heterozygous is the scientific term).

Single mutants have one copy of the CCR5 gene and that copy makes CCR5.

So the single mutants have CCR5, just not as much as normal people with non-mutant DNA.

Since the single mutants have less CCR5, then it is probably easier for LL to block the CCR5 because it takes less LL to do the job.

Single mutants still get covid so they will be present in every trial, including CD12.

Single mutants constitute around 10% of the human population.

So every covid clinical trial has about 10% of its participants who are single mutants, and theoretically those 10% should respond better to LL.